Stem Cell Therapy for Musculoskeletal Injuries

At Stem Cells Transplant Institute in Costa Rica, we offer stem cell therapy programs designed to support the body’s natural repair processes for musculoskeletal injuries involving tendons, ligaments, muscles, and meniscal tissue. Our MSC-based protocols are used alongside physical therapy and orthopedic care to help modulate inflammation, support tissue recovery, and promote functional rehabilitation through a personalized regenerative medicine approach.

Reviewed: 11 May 2026

What are Musculoskeletal Injuries?

Musculoskeletal injuries includes damage to tendons (such as the rotator cuff or Achilles tendon), ligaments (including ACL and MCL injuries), meniscal tears, and chronic tendinopathies. These conditions can lead to pain, reduced mobility, weakness, and limitations in daily or athletic activities.

Management of musculoskeletal injuries varies depending on severity and chronicity and may involve rehabilitation, medical management, or surgical evaluation in selected cases.

According to the World Health Organization (2023), musculoskeletal conditions affect more than 1.7 billion people worldwide, making them one of the leading causes of pain, disability, and reduced mobility across all age groups.

Why Seek Stem Cell Therapy for Musculoskeletal Injuries in Costa Rica?

Stem cell therapy for tendon tears, ligament injuries, and chronic tendinopathies that have not responded to conservative treatment is offered in San José, Costa Rica at the Stem Cells Transplant Institute, a certified clinical facility.

Patients from the United States, Canada, and Europe travel to San José to access physician-supervised mesenchymal stem cell (MSC) protocols. Treatment programs are typically completed over two to three days, with post-procedure activity recommendations tailored to the specific injury and clinical context. By traveling to Costa Rica, costs are significantly less than equivalent procedures in North American private clinics.

Before scheduling therapy, imaging studies—preferably MRI—are reviewed to assess the extent and location of tissue damage. Our treatment protocols are tailored to the structure involved, severity of injury, and prior therapies. Some conditions, such as rotator cuff tears and Achilles tendinopathy, require different clinical approaches.

Common Characteristics

Localized pain and functional weakness
Reduced range of motion and decreased strength
Persistent inflammation or delayed tissue healing in long-standing cases

Evidence-Based Treatment

Why Stem Cell Therapy for Injuries?

MSCs are studied primarily for their paracrine activity — meaning they release signaling molecules that help modulate inflammation, influence cellular communication, and support biological processes involved in tissue remodeling and recovery.

Under experimental and preclinical conditions, MSCs have demostrated the capacity to differentiate into specialized cell types. In clinical musculoskeletal applications, current evidence suggests their principal role is not direct tissue replacement, but rather the creation of a supportive biological environment that may assist the body’s intrinsic repair mechanisms.

In selected cases, stem cell–based approaches are explored as part of conservative or adjunctive management strategies and may help some patients postpone or reconsider surgical intervention, depending on clinical evolution and rehabilitation progress.

Evidence remains preliminary, and ongoing controlled clinical trials are required to confirm the magnitude and consistency of these effects.

Supporting tissue remodeling

MSCs release natural growth factors and signaling molecules that may support biological processes involved in tendon and ligament remodeling and organization during recovery (Jiang et al., 2023)

Modulation of inflammation

MSCs are known to secrete anti-inflammatory mediators, including cytokines and extracellular vesicles, which may help regulate inflammatory activity associated with musculoskeletal injury. (Cho et al., 2021)

Support of extracellular matrix organization

MSC-related signaling may influence cells responsible for collagen production, the primary structural component of tendons and ligaments, potentially supporting more organized tissue architecture during rehabilitation (Ruiz-Alonso et al., 2021).

Expected Benefits and Clinical Observations

Although individual responses vary widely, published studies and clinical observations have reported potential supportive improvement in the following functional domains:

Pain reduction

40-60%

Improved strength and perceived tissue quality

35-50%

Reduced stiffness

30-45%

Support of recovery processes

25-40%

*These percentages summarizes ranges reported in selected clinical studies and observational cohorts under controlled conditions and standardized outcomes measures. They are not specific to any single study or to treatments performed at Stem Cells Transplant Institute. They should not be interpreted as averages, promises, or guaranteed results for individual patients. Evidence for MSC therapy in musculoskeletal injuries remains preliminary, and ongoing controlled clinical trials are still evaluating the magnitude, durability and consistency of these effects. All observations should be considered exploratory and hypothesis-generating rather than definitive proof of efficacy.

Timeline of Reported Improvements

Published studies and patient-reported outcomes suggest that changes following mesenchymal stem cell (MSC)-based therapies for musculoskeletal injuries may develop gradually over time. These timelines are illustrative summaries rather than predictions, and individual responses vary significantly.

1-3 months

Initial changes such as reduced local discomfort, swelling, or symptom awareness reported by some patients.

3-6 months

Functional changes and strength-related improvements reported in certain cohorts, often in conjunction with ongoing rehabilitation.

6-12 months

Maintenance of reported functional improvements in some patients who complete structured rehabilitation programs.

*These timelines summarize patterns reported across selected published studies and observational cohorts. They are not specific predictions, and they do not represent expected outcomes for any individual patient. Individual experiences vary considerably, and some patients may experience minimal or no improvement. Evidence for MSC therapy for musculoskeletal injuries remains preliminary, and larger controlled clinical trials are needed to validate these observations. All timelines should be interpreted as exploratory and non-confirmatory.

Patient Stories & Testimonials

Frequently Asked Questions

Mesenchymal stem cell (MSC)–based therapies have been explored as supportive options in certain soft-tissue musculoskeletal conditions, including tendon injuries (such as rotator cuff or Achilles tendon involvement), ligament injuries (including ACL or MCL sprains), meniscal damage, and some chronic overuse or degenerative conditions.

These approaches are intended to help support the biological environment surrounding the injured tissue, potentially assisting the body’s intrinsic repair and recovery processes when used alongside appropriate rehabilitation and medical care. Suitability varies by condition, severity, and individual patient factors, and not all injuries or patients are candidates for this type of therapy.

Many patients notice gradual changes over several weeks, with some reporting more noticeable improvements between 1–3 months. Research suggests that MSCs may continue to release biologically active signals for several months, so changes may continue to develop for 6 months or more. Recovery timelines vary depending on the injury, its severity, and individual patient factors.

Yes. In clinical practice, stem cell therapy is often combined with a tailored rehabilitation program. Physical therapy, strengthening exercises, stretching routines, and sometimes supportive treatments such as bracing or manual therapy can be used alongside MSC therapy to help support recovery and functional outcomes.

Most programs use mesenchymal stem cells (MSCs) because they are well-studied for their anti-inflammatory and tissue-supportive properties. Depending on your medical profile, MSCs may be obtained from your own body (such as adipose tissue or bone marrow) or from carefully screened umbilical-cord donations, in accordance with applicable regulatory requirements.

Mesenchymal Stem Cells for Tendon and Ligament Injuries

Medical Archives • 2020

Clinical evidence review evaluating therapeutic outcomes and regenerative potential of mesenchymal stem cells in tendon and ligament injuries.

Stem Cell Approaches for Tendon Repair

Journal of Physiology • 2025

Scientific review examining mechanisms, current evidence, and future therapeutic insights of stem cell-based strategies for tendon regeneration.

Allogenic Adipose MSC Therapy for Tendon Injury

ClinicalTrials.gov Registry

Registered clinical trial evaluating safety and therapeutic effects of allogenic adipose-derived mesenchymal stem cells for tendon injury treatment.

MSC Secretome in Chronic Tendon Injury Healing

tem Cells Cloning • 2025

Experimental study showing mesenchymal stem cell secretome enhanced collagen production and tissue repair in chronic tendon injury models.

info

Location

San José, Costa Rica

info@stemcellstransplantinstitute.com

Call Center

+1 888 785-4170

APPLY TODAY